Federal Marijuana Policy: From Hemp Promotion to Decades of Denial and Recent Rescheduling Shifts

James Bovard's analysis in ZeroHedge highlights a century of federal inconsistency on cannabis, arguing it exemplifies why trust in government drug regulation is misplaced. Historical records confirm the U.S. Department of Agriculture supported hemp cultivation in the early 20th century for industrial uses like rope and paper, with production documented in multiple states before the 1930s decline.[1][2] The Marihuana Tax Act of 1937 effectively criminalized marijuana despite prior medical recognition; the American Medical Association strongly opposed the bill, with legislative counsel Dr. William C. Woodward testifying there was no evidence of addiction from medical use and warning it would restrict legitimate practice.[3][4] For over 50 years afterward, marijuana remained Schedule I, defined as having no accepted medical use.

Legal challenges underscore the pattern. NORML's 1972 petition for rescheduling led to court-ordered reviews; a 1988 DEA administrative law judge ruled cannabis had accepted medical use and should move to Schedule II, but the DEA administrator rejected it, a decision upheld on appeal.[5][6] Recent developments align with the article's timeline: On December 18, 2025, President Trump signed an executive order directing expedited research and rescheduling efforts.[7][8] On April 23, 2026, Acting Attorney General Todd Blanche announced the shift of FDA-approved marijuana-derived products and state-licensed medical marijuana to Schedule III.[9][10]

This trajectory—from early agricultural support and medical acknowledgment to prohibition, prolonged denial of medical utility despite internal judicial findings, and partial recent reversal—illustrates systemic delays in aligning policy with evidence. It challenges narratives of federal agencies as neutral arbiters, revealing how political, bureaucratic, and enforcement priorities have shaped drug classification more than consistent science.